Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | PRKACA | P17612 | 3/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.51 |
| ▸ | OGFRL1 | Q5TC84 | 10/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635863 | 0.93 | SMN1; SMN2 (0.53) | TP53PRKACARPS6KB1GSK3BROCK1 | |
| SCHEMBL6598052 | 0.83 | OPRM1 (0.52) | TP53OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL6594414 | 0.82 | OPRM1 (0.54) | TP53OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL6594532 | 0.82 | OPRM1 (0.54) | TP53OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL6595311 | 0.82 | OPRM1 (0.54) | TP53OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL31267382 | 0.80 | TP53 (0.54) | TP53PRKACARPS6KB1GSK3BROCK1 | |
| SCHEMBL13543533 | 0.80 | SMN1; SMN2 (0.44) | TP53OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3526098 | 0.80 | SMN1; SMN2 (0.44) | TP53OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL6593749 | 0.79 | OPRM1 (0.53) | OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL2929873 | 0.79 | RPS6KB1 (0.58) | TP53PRKACARPS6KB1GSK3BROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048862-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048862-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048862-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110059047-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059047-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059047-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2282762-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009142842-A9 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009142842-A9 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009142842-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009142842-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | TP53 1652/4885PRKACA 3191/4885RPS6KB1 531/4885 |
| US-20110059047-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | TP53 1652/4885PRKACA 3191/4885RPS6KB1 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.